Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC)

By K. Livingstone, M. Fisher. 2007

1,086 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/f43a70028823b22a5cf9ae108799ab3b85e3a6ef

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. V. Basevi
2. G. Bakris
3. D. Nathan
4. M. S. Kirkman
5. Gerald I. Shulman
6. S. Grundy
7. Ralph DeFronzo
8. V. Samuel

In Surgery

1. G. Bakris
2. D. Nathan
3. I. D. de Boer
4. M. S. Kirkman
5. V. Basevi

Citations in the corpus

• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. (2020, background): “up of subjects from the DCCT more than 10 years after the active treatment component of the study demonstrated less macrovascular as well as less microvascular complications in the group that received intensive treatment (2,4).”
• Standards of Medical Care in Diabetes—2013 (2012, background): “The DCCT clearly showed that intensive insulin therapy (three or more injections per day of insulin, CSII, or insulin pump therapy) was a key part of improved glycemia and better outcomes (71,92).”
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview (2013, background): “The clinical expression of these changes, fatal and nonfatal myocardial infarctions and stroke, were also reduced by INT, with a 58% reduction in CVD events after a mean of 18 years of followup from the beginning of the DCCT (40).”
• Standards of Medical Care in Diabetes—2012 (2011, background): “In the DCCT, there was a trend toward lower risk of CVD events with intensive control, and in 9-year post-DCCT follow-up of the EDIC cohort participants previously randomized to the intensive arm had a significant 42% reduction in CVD outcomes and a significant 57% reduction in the risk of nonfatal ”
• Standards of Medical Care in Diabetes—2014 (2013, background): “The benefit of intensive glycemic control in this type 1 diabetic cohort has recently been shown to persist for several decades (93).”
• Roux-en-Y Gastric Bypass versus Intensive Medical Management for the Control of Type 2 Diabetes, Hypertension and Hyperlipidemia: An International, Multicenter, Randomized Trial (2013, background): “0% or less protects against vascular complications of type 1 diabetes.(17,18) Decreasing LDL cholesterol and blood pressure reduce the risk of macrovascular events in populations of patients with diabetes.”
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. (2021, background): “Follow-up of subjects from the DCCT more than 10 years after the active treatment component of the study demonstrated fewer macrovascular as well as fewer microvascular complications in the group that received intensive treatment (2,4).”
• 6. Glycemic Targets: Standards of Medical Care in Diabetes—2020 (2019, methodology): “In the 9-year post-DCCT follow-up of the EDIC cohort, participants previously randomized to the intensive arm had a significant 57% reduction in the risk of nonfatal myocardial infarction (MI), stroke, or cardiovascular death compared with those previously randomized to the standard arm (32).”
• Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes (2016, background): “Studies have shown clear improvements in the risk for or progression of microvascular complications and cardiovascular disease with intensive insulin therapy (≥3 injections of insulin per day) or continuous subcutaneous insulin infusion compared with 1 or 2 injections per day (6, 20).”